Evidence map›Paper›PMID 42595800›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Comparative performance of

Laura García Belaustegui, Magdalena de la Higuera López-Frías, Jorge de Abajo-Larriba, Andrés Basanta Mota, Juan Fernando Bastidas, María Isabel Morales Lozano, Fabiana Grissanti, Javier Arbizu

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Laura García BelausteguiDepartment of Nuclear Medicine, Clínica Universidad de Navarra, Madrid, Spain.ORCID http://orcid.org/0000-0001-9502-5734
Magdalena de la Higuera López-FríasDepartment of Endocrinology, Clínica Universidad de Navarra, Madrid, Spain. mhiguera@unav.es.ORCID http://orcid.org/0000-0003-1637-9310
Jorge de Abajo-LarribaDepartment of Otorhinolaryngology, Clínica Universidad de Navarra, Madrid, Spain.
Andrés Basanta MotaDepartment of Nuclear Medicine, Clínica Universidad de Navarra, Madrid, Spain.
Juan Fernando BastidasDepartment of Nuclear Medicine, Clínica Universidad de Navarra, Madrid, Spain.
María Isabel Morales LozanoDepartment of Nuclear Medicine, Clínica Universidad de Navarra, Madrid, Spain.
Fabiana GrissantiDepartment of Nuclear Medicine, Clínica Universidad de Navarra, Madrid, Spain.
Javier ArbizuDepartment of Nuclear Medicine, Clínica Universidad de Navarra, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the diagnostic performance of [¹¹C]methionine (MET) PET/CT for preoperative localisation in primary hyperparathyroidism (PHPT) with negative or inconclusive first-line imaging, and to compare it with [¹¹C]choline (CHO) PET/CT in a head-to-head analysis, focusing on determinants of adenoma detectability.

methodsFifty-one patients with biochemically confirmed PHPT underwent MET PET/CT following inconclusive conventional imaging. In a subgroup of 25 patients, CHO PET/CT was also performed. Imaging findings were correlated with surgical and histopathological results. Detection rates and positive predictive values (PPV) were calculated, and semiquantitative parameters, including standardized uptake value (SUV) and lesion-to-background ratio (LBR), were analysed. Associations between PET findings, biochemical markers, and adenoma weight were explored.

resultsMET PET/CT achieved a patient-based detection rate of 76.5% with a PPV of 88.2%. In the head-to-head subgroup, CHO detected more lesions than MET (27 vs. 14; p = 0.0025) and identified all histologically confirmed adenomas, with comparable PPVs (90.0% vs. 77.8%). CHO demonstrated significantly higher SUV and LBR values. Adenoma weight was significantly associated with PET findings: MET-positive adenomas were significantly heavier than MET-negative adenomas, whereas CHO maintained high lesion detection even in adenomas weighing 0.5 g or less. Additionally, a trend towards higher uptake with increasing PTH and calcium levels was observed for CHO SUVmax.

conclusionAdenoma weight appears to be a major determinant of PET detectability in PHPT. The ability of CHO PET/CT to detect adenomas weighing 0.5 g or less, which may remain occult on MET, provides a plausible explanation for its superior lesion detection, while both tracers maintain a high positive predictive value. These findings further support the use of choline-based PET imaging in patients with inconclusive first-line studies.

Indexed as

[11C]choline[11C]methionineParathyroid adenomaPET/CTPrimary hyperparathyroidism

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.